Literature DB >> 18071636

The bone microenvironment in metastasis; what is special about bone?

Karen M Bussard1, Carol V Gay, Andrea M Mastro.   

Abstract

The skeleton is a common destination for many cancer metastases including breast and prostate cancer. There are many characteristics of bone that make it an ideal environment for cancer cell migration and colonization. Metaphyseal bone, found at the ends of long bone, in ribs, and in vertebrae, is comprised of trabecular bone interspersed with marrow and rich vasculature. The specialized microvasculature is adapted for the easy passage of cells in and out of the bone marrow. Moreover, the metasphyseal regions of bone are constantly undergoing remodeling, a process that releases growth factors from the matrix. Bone turnover also involves the production of numerous cytokines and chemokines that provide a means of communication between osteoblasts and osteoclasts, but co-incidentally can also attract and support metastatic cells. Once in the marrow, cancer cells can interact directly and indirectly with osteoblasts and osteclasts, as well as hematopoietic and stromal cells. Cancer cells secrete factors that affect the network of cells in the bone microenvironment as well as interact with other cytokines. Additionally, transient cells of the immune system may join the local mileau to ultimately support cancer cell growth. However, most metastasized cells that enter the bone marrow are transient; a few may remain in a dormant state for many years. Advances in understanding the bone cell-tumor cell interactions are key to controlling, if not preventing metastasis to bone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18071636     DOI: 10.1007/s10555-007-9109-4

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  102 in total

Review 1.  Imaging of bone metastasis: An update.

Authors:  Gerard J O'Sullivan; Fiona L Carty; Carmel G Cronin
Journal:  World J Radiol       Date:  2015-08-28

Review 2.  Metastasis Organotropism: Redefining the Congenial Soil.

Authors:  Yang Gao; Igor Bado; Hai Wang; Weijie Zhang; Jeffrey M Rosen; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

3.  A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone.

Authors:  Simone Bersini; Jessie S Jeon; Gabriele Dubini; Chiara Arrigoni; Seok Chung; Joseph L Charest; Matteo Moretti; Roger D Kamm
Journal:  Biomaterials       Date:  2013-12-31       Impact factor: 12.479

4.  The use of chemokine-releasing tissue engineering scaffolds in a model of inflammatory response-mediated melanoma cancer metastasis.

Authors:  Cheng-Yu Ko; Lanxiao Wu; Ashwin M Nair; Yi-Ting Tsai; Victor K Lin; Liping Tang
Journal:  Biomaterials       Date:  2011-10-22       Impact factor: 12.479

5.  Bone targeted therapies in early breast cancer.

Authors:  Keo Tabane; Daniel A Vorobiof
Journal:  Curr Treat Options Oncol       Date:  2011-12

6.  Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.

Authors:  Junhua Mai; Yi Huang; Chaofeng Mu; Guodong Zhang; Rong Xu; Xiaojing Guo; Xiaojun Xia; David E Volk; Ganesh L Lokesh; Varatharasa Thiviyanathan; David G Gorenstein; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  J Control Release       Date:  2014-05-10       Impact factor: 9.776

Review 7.  Adenosine and bone metabolism.

Authors:  Aránzazu Mediero; Bruce N Cronstein
Journal:  Trends Endocrinol Metab       Date:  2013-03-14       Impact factor: 12.015

8.  Development and characterization of murine models of medulloblastoma extraneural growth in bone.

Authors:  Jessica M Grunda; Dezhi Wang; Gregory A Clines
Journal:  Clin Exp Metastasis       Date:  2013-03-15       Impact factor: 5.150

Review 9.  Mechanisms of bone metastases of breast cancer.

Authors:  Larry J Suva; Robert J Griffin; Issam Makhoul
Journal:  Endocr Relat Cancer       Date:  2009-05-14       Impact factor: 5.678

10.  Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Authors:  Fraser Conrad; Xiaodong Zhu; Xin Zhang; Robert J Chalkley; Alma L Burlingame; James D Marks; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2009-02-14       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.